News | October 31, 2023
Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Subscribe To Our Newsletter & Stay Updated
